FOXP2 and diffuse large B-cell lymphoma: The qualitative intensity of FOXP2 expression (score 0–1 versus 2–3) also identified a subgroup of DLBCL patients (n = 15) with poor clinical outcome (OS, P = 0.0027; PFS, P = 0.0093) (Figure 2E–2F).